Coherus Oncology, Inc.'s Q2 2025 Earnings Call Transcriptcript - verbatim, without quotation marks, detailing their quarterly financial results and future outlooks shared during the 2025 Q2 conference call.
Coherus Oncology Reports Q2 2025 Results, Showing Strong Growth in LOQTORZI Sales
Coherus Oncology Inc. (CHRS) recently held a Q2 2025 Earnings Conference Call on August 7, 2025, at 5:00 PM ET. The call was led by Jodi Sievers, Head of Investor Relations for Coherus, and included key executives such as Sameer Goregaoker, Executive Vice President, Commercial, Dr. Rosh Dias, Chief Medical Officer, Dr. Theresa Lavallee, Chief Scientific and Development Officer, and Dennis M. Lanfear, Chief Executive Officer.
The call began with a reminder that it includes forward-looking statements. The unnamed operator then handed over the call to Jordan, who led the proceedings.
The highlight of the call was the strong performance of Coherus' key oncology product, LOQTORZI, which saw a 36% quarter-over-quarter increase in net revenue to $10 million. This growth surpassed analyst expectations by over 10%, primarily driven by expanding sales. Despite this revenue growth, the company recorded a Q2 net loss from continuing operations of $44.9 million (about $0.39 per share) and a non-GAAP loss per share of $0.34, due to elevated R&D expenses.
Coherus' financial position remains solid, with $238 million in cash at quarter-end. This strong financial position was bolstered by the completion of the UDENYCA divestiture for $483.4 million plus potential milestone payments up to $75 million.
The company also provided updates on its pipeline, with key data expected for CHS-114 (a cytolytic CCR8 antibody) and casdozokitug (a first-in-class IL-27 antagonist) in the first half of 2026, signalling ongoing R&D investment and future growth potential.
From the earnings call and market reaction, the sentiment appeared cautiously positive. The growing LOQTORZI sales underpin revenue momentum, and asset sales strengthen the balance sheet. However, losses persist, and the company remains dependent on a limited oncology portfolio, highlighting risks as well as opportunities. Coherus is focused on advancing its novel pipeline and potentially expanding LOQTORZI licensing in the U.S. and international markets.
Participants from other companies included Colleen Margaret Kusy from Robert W. Baird & Co. Incorporated, Research Division, Douglas Dylan Tsao from H.C. Wainwright & Co, LLC, Research Division, Jason Wesly McCarthy from Maxim Group LLC, Research Division, Li Chen from an unidentified company, Lut Ming Cheng from JPMorgan Chase & Co, Research Division, and Michael Thomas Nedelcovych from TD Cowen, Research Division.
Participants were advised to refer to the press release and Form 10-Q for information on risks and uncertainties.
\n\n [1] Coherus Oncology Inc. (CHRS) Q2 2025 Earnings Conference Call Transcript. (2025, August 7). Seeking Alpha. Retrieved from https://seekingalpha.com/news/3768282-coherus-oncology-inc-chrs-q2-2025-earnings-conference-call-transcript
\n\n [2] Coherus Oncology Q2 2025 Earnings Call Transcript. (2025, August 7). The Motley Fool. Retrieved from https://www.fool.com/earnings/call-transcripts/2025/08/07/coherus-oncology-chrs-q2-2025-earnings-call-transcript/
\n\n [3] Coherus Oncology Q2 2025 Earnings Call Transcript. (2025, August 7). Yahoo Finance. Retrieved from https://finance.yahoo.com/news/coherus-oncology-q2-2025-earnings-165300068.html
- Coherus Oncology is investing in its pipeline, with key data expected for CHS-114 and casdozokitug in the first half of 2026, demonstrating ongoing research and development (R&D) investment and potential future growth.
- The strong growth in LOQTORZI sales, which increased by 36% QoQ to $10 million, is a significant aspect of Coherus' business strategy, contributing to revenue momentum and underpinning its financial position.
